Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Nicolas Roche; Megan L. Crichton; Pieter C. Goeminne; Bin Cao; Marc Humbert; Michal Shteinberg; Katerina M. Antoniou; Charlotte Suppli Ulrik; Helen Parks; Chen Wang; Thomas Vandendriessche; Jieming Qu; Daiana Stolz; Christopher Brightling; Tobias Welte; Stefano Aliberti; Anita K. Simonds; Thomy Tonia; James D. Chalmers

doi:10.1183/13993003.00803-2022

Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Nicolas Roche, Megan L. Crichton, Pieter C. Goeminne, Bin Cao, Marc Humbert, Michal Shteinberg, Katerina M. Antoniou, Charlotte Suppli Ulrik, Helen Parks, Chen Wang, Thomas Vandendriessche, Jieming Qu, Daiana Stolz, Christopher Brightling, Tobias Welte, Stefano Aliberti, Anita K. Simonds, Thomy Tonia, James D. Chalmers^*

^*Corresponding author for this work

Research output: Contribution to journal › Review › Research › peer-review

32 Citations (Scopus)

7 Downloads (Pure)

Original language	English
Article number	2200803
Journal	European Respiratory Journal
Volume	60
Issue number	2
ISSN	0903-1936
DOIs	https://doi.org/10.1183/13993003.00803-2022
Publication status	Published - 2022

Access to Document

10.1183/13993003.00803-2022Licence: CC BY

FulltextFinal published version, 4.79 MBLicence: CC BY

Cite this

Roche, N., Crichton, M. L., Goeminne, P. C., Cao, B., Humbert, M., Shteinberg, M., Antoniou, K. M., Ulrik, C. S., Parks, H., Wang, C., Vandendriessche, T., Qu, J., Stolz, D., Brightling, C., Welte, T., Aliberti, S., Simonds, A. K., Tonia, T., & Chalmers, J. D. (2022). Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 60(2), [2200803]. https://doi.org/10.1183/13993003.00803-2022

Update June 2022 : management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. / Roche, Nicolas; Crichton, Megan L.; Goeminne, Pieter C.; Cao, Bin; Humbert, Marc; Shteinberg, Michal; Antoniou, Katerina M.; Ulrik, Charlotte Suppli; Parks, Helen; Wang, Chen; Vandendriessche, Thomas; Qu, Jieming; Stolz, Daiana; Brightling, Christopher; Welte, Tobias; Aliberti, Stefano; Simonds, Anita K.; Tonia, Thomy; Chalmers, James D.

In: European Respiratory Journal, Vol. 60, No. 2, 2200803, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Roche, N, Crichton, ML, Goeminne, PC, Cao, B, Humbert, M, Shteinberg, M, Antoniou, KM, Ulrik, CS, Parks, H, Wang, C, Vandendriessche, T, Qu, J, Stolz, D, Brightling, C, Welte, T, Aliberti, S, Simonds, AK, Tonia, T & Chalmers, JD 2022, 'Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline', European Respiratory Journal, vol. 60, no. 2, 2200803. https://doi.org/10.1183/13993003.00803-2022

Roche, Nicolas ; Crichton, Megan L. ; Goeminne, Pieter C. ; Cao, Bin ; Humbert, Marc ; Shteinberg, Michal ; Antoniou, Katerina M. ; Ulrik, Charlotte Suppli ; Parks, Helen ; Wang, Chen ; Vandendriessche, Thomas ; Qu, Jieming ; Stolz, Daiana ; Brightling, Christopher ; Welte, Tobias ; Aliberti, Stefano ; Simonds, Anita K. ; Tonia, Thomy ; Chalmers, James D. / Update June 2022 : management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. In: European Respiratory Journal. 2022 ; Vol. 60, No. 2.

@article{2f3e88a0e8a24d44a4c486c336eac277,

title = "Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline",

author = "Nicolas Roche and Crichton, {Megan L.} and Goeminne, {Pieter C.} and Bin Cao and Marc Humbert and Michal Shteinberg and Antoniou, {Katerina M.} and Ulrik, {Charlotte Suppli} and Helen Parks and Chen Wang and Thomas Vandendriessche and Jieming Qu and Daiana Stolz and Christopher Brightling and Tobias Welte and Stefano Aliberti and Simonds, {Anita K.} and Thomy Tonia and Chalmers, {James D.}",

note = "Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from GSK, AstraZeneca, Chiesi, Sanofi and Zambon, outside the submitted work. M.L. Crichton reports personal fees from AstraZeneca, outside the submitted work. P.C. Goeminne reports personal fees for lectures from GSK and AstraZeneca, grants, personal fees for advisory board work and non-financial support for meeting attendance from Chiesi, outside the submitted work. B. Cao reports personal fees from F. Hoffmann-La Roche Ltd as a member of steering committee in transmission study of baloxavir, and grants from Peking Union Medical College Foundation, outside the submitted work. M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck, grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. M. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Boehringer Ingelheim, AstraZeneca, Kamada, Vertex pharmaceuticals, Teva and Zambon, non-financial support from Actelion and Rafa, outside the submitted work. C.S. Ulrik reports personal fees from AstraZeneca, GSK, Chiesi, Orion Pharma and TEVA, grants and personal fees from Boehringer Ingelheim, Sanofi Genzyme and Novartis, grants from Mundipharma, outside the submitted work. D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, lecture fees from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG and Vifor AG, outside the submitted work. T. Welte reports grants from German Ministry of Health, German Ministry of Research and Education, DFG, WHO and EU, during the conduct of the study; personal fees for lectures/advisory board work from Roche, AstraZeneca, Boehringer, GSK and Novartis, outside the submitted work. S. Aliberti reports personal fees for advisory board work and research support from Bayer Healthcare, personal fees for lectures from Grifols and Menarini, personal fees for advisory board work from AstraZeneca and ZetaCube Srl, personal fees for advisory board work and lectures from Zambon and GlaxoSmithKline, grants and personal fees advisory board work and lectures from Chiesi and INSMED, grants from Fisher & Paykel, outside the submitted work. T. Tonia acts as ERS Methodologist. J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed, personal fees from Chiesi, Novartis and Zambon, grants from Gilead Sciences, outside the submitted work. The remaining authors disclose no potential conflicts of interest. Funding Information: Funded by the European Respiratory Society through the COVID-19 Living Guidelines Task Force (2020-14). Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2022",

doi = "10.1183/13993003.00803-2022",

language = "English",

volume = "60",

journal = "The European respiratory journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - Update June 2022

T2 - management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

AU - Roche, Nicolas

AU - Crichton, Megan L.

AU - Goeminne, Pieter C.

AU - Cao, Bin

AU - Humbert, Marc

AU - Shteinberg, Michal

AU - Antoniou, Katerina M.

AU - Ulrik, Charlotte Suppli

AU - Parks, Helen

AU - Wang, Chen

AU - Vandendriessche, Thomas

AU - Qu, Jieming

AU - Stolz, Daiana

AU - Brightling, Christopher

AU - Welte, Tobias

AU - Aliberti, Stefano

AU - Simonds, Anita K.

AU - Tonia, Thomy

AU - Chalmers, James D.

N1 - Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from GSK, AstraZeneca, Chiesi, Sanofi and Zambon, outside the submitted work. M.L. Crichton reports personal fees from AstraZeneca, outside the submitted work. P.C. Goeminne reports personal fees for lectures from GSK and AstraZeneca, grants, personal fees for advisory board work and non-financial support for meeting attendance from Chiesi, outside the submitted work. B. Cao reports personal fees from F. Hoffmann-La Roche Ltd as a member of steering committee in transmission study of baloxavir, and grants from Peking Union Medical College Foundation, outside the submitted work. M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck, grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. M. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Boehringer Ingelheim, AstraZeneca, Kamada, Vertex pharmaceuticals, Teva and Zambon, non-financial support from Actelion and Rafa, outside the submitted work. C.S. Ulrik reports personal fees from AstraZeneca, GSK, Chiesi, Orion Pharma and TEVA, grants and personal fees from Boehringer Ingelheim, Sanofi Genzyme and Novartis, grants from Mundipharma, outside the submitted work. D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, lecture fees from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG and Vifor AG, outside the submitted work. T. Welte reports grants from German Ministry of Health, German Ministry of Research and Education, DFG, WHO and EU, during the conduct of the study; personal fees for lectures/advisory board work from Roche, AstraZeneca, Boehringer, GSK and Novartis, outside the submitted work. S. Aliberti reports personal fees for advisory board work and research support from Bayer Healthcare, personal fees for lectures from Grifols and Menarini, personal fees for advisory board work from AstraZeneca and ZetaCube Srl, personal fees for advisory board work and lectures from Zambon and GlaxoSmithKline, grants and personal fees advisory board work and lectures from Chiesi and INSMED, grants from Fisher & Paykel, outside the submitted work. T. Tonia acts as ERS Methodologist. J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed, personal fees from Chiesi, Novartis and Zambon, grants from Gilead Sciences, outside the submitted work. The remaining authors disclose no potential conflicts of interest. Funding Information: Funded by the European Respiratory Society through the COVID-19 Living Guidelines Task Force (2020-14). Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2022

Y1 - 2022

U2 - 10.1183/13993003.00803-2022

DO - 10.1183/13993003.00803-2022

M3 - Review

C2 - 35710264

AN - SCOPUS:85136339483

VL - 60

JO - The European respiratory journal

JF - The European respiratory journal

SN - 0903-1936

IS - 2

M1 - 2200803

ER -